Fate Therapeutics Inc FATE:NASDAQ

Last Price$14.72Cboe Real-Time Last Sale as of 3:26PM ET 10/15/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.59(4.18%)
Bid (Size)$14.71 (200)
Ask (Size)$14.73 (200)
Day Low / High$13.93 - 14.74
Volume428.9 K

Fate Therapeutics Says First Patient Treated With Cancer Therapy Completes Initial Safety Assessment

8:28AM ET 4/02/2019 MT Newswires
Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said pre-market Tuesday that the first patient treated with its cancer drug FT500 "successfully" completed an initial safety assessment.

The patient received three once weekly doses of FT500, and the treatment cycle was well-tolerated with no dose-limiting toxicities or serious adverse events reported during the initial 28-day observation period, the company said in a statement.

FT500 is a natural killer cell cancer immunotherapy. It is the first-ever cell therapy derived from an "induced pluripotent stem cell" (iPSC) administered to a patient in the US.

The company said that new preclinical data of universal, off-the-shelf, iPSC-derived NK cell product candidates -- FT516 and FT596 -- have also been highlighted at the 2019 AACR (American Association for Cancer Research) annual meeting.

Price: 17.56, Change: -0.01, Percent Change: -0.06